Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29932Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | VAN WIJMEERSCH, Bart | - |
| dc.contributor.author | Buffels, R. | - |
| dc.contributor.author | Clinch, S. | - |
| dc.contributor.author | Kuhelj, R. | - |
| dc.contributor.author | Wei, W. | - |
| dc.contributor.author | Vermersch, P. | - |
| dc.date.accessioned | 2019-11-12T13:31:32Z | - |
| dc.date.available | 2019-11-12T13:31:32Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | MULTIPLE SCLEROSIS JOURNAL, 25(S2), p. 824-825 | - |
| dc.identifier.issn | 1352-4585 | - |
| dc.identifier.uri | http://hdl.handle.net/1942/29932 | - |
| dc.description.sponsorship | Sponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK. B. Van Wijmeersch has received financial support/study grants and fees for speaking and serving on advisory boards from Bayer, Biogen, F. Hoffmann-La Roche Ltd, Genzyme/Sanofi, Merck Serono, Novartis and Teva. | - |
| dc.language.iso | en | - |
| dc.publisher | SAGE PUBLICATIONS LTD | - |
| dc.subject.other | Clinical Neurology; Neurosciences | - |
| dc.title | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | - |
| dc.type | Journal Contribution | - |
| local.bibliographicCitation.conferencedate | SEP 11-13, 2019 | - |
| local.bibliographicCitation.conferencename | 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS | - |
| local.bibliographicCitation.conferenceplace | Stockholm, SWEDEN | - |
| dc.identifier.epage | 825 | - |
| dc.identifier.issue | S2 | - |
| dc.identifier.spage | 824 | - |
| dc.identifier.volume | 25 | - |
| local.format.pages | 2 | - |
| local.bibliographicCitation.jcat | M | - |
| dc.description.notes | [Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Overpelt, Belgium. [Buffels, R.; Kuhelj, R.; Wei, W.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Clinch, S.] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England. [Vermersch, P.] Univ Lille, Lille, France. | - |
| local.publisher.place | LONDON | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Meeting Abstract | - |
| dc.identifier.isi | 000485303103278 | - |
| item.fulltext | No Fulltext | - |
| item.contributor | VAN WIJMEERSCH, Bart | - |
| item.contributor | Buffels, R. | - |
| item.contributor | Clinch, S. | - |
| item.contributor | Kuhelj, R. | - |
| item.contributor | Wei, W. | - |
| item.contributor | Vermersch, P. | - |
| item.fullcitation | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W. & Vermersch, P. (2019) Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies. In: MULTIPLE SCLEROSIS JOURNAL, 25(S2), p. 824-825. | - |
| item.accessRights | Closed Access | - |
| crisitem.journal.issn | 1352-4585 | - |
| crisitem.journal.eissn | 1477-0970 | - |
| Appears in Collections: | Research publications | |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.